OSSTEC Raises $8M for 3D-Printed ASCENT Knee Implant
OSSTEC has raised $8 million to advance its ASCENT cementless partial-knee system and CLARITY instruments in the United States, targeting FDA clearance and first U.S. procedures in the first half of 2027.

UK orthopedic company OSSTEC has raised $8 million to advance ASCENT, its fixed-bearing cementless partial-knee system. EMBRYO Ventures led the round, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures.
ASCENT is based on a 3D-printed biomimetic fixation structure intended to support biological fixation without bone cement. The funding will support the FDA pathway for ASCENT and its CLARITY instruments, surgeon training and U.S. launch preparation. OSSTEC is planning first U.S. human procedures in the first half of 2027.
The financing and development timeline come from OSSTEC and its investors; they are not clinical-performance results. ASCENT and CLARITY are not FDA-cleared and are not available for sale in the United States.
Key facts
- The financing totals $8 million
- EMBRYO Ventures led the round
- ASCENT uses a 3D-printed biomimetic fixation structure
- ASCENT and CLARITY are not FDA-cleared or available for sale in the U.S.
Context
The financing moves a 3D-printed fixation platform toward regulatory review and planned first clinical use in partial-knee replacement.


